Last reviewed 2026-06-02 · How we verify

Selecal (TILISOLOL)

Phase 2 active Small molecule ✓ Verified May 2026

Selecal (generic name: TILISOLOL) is a tilisolol drug. It is currently in Phase 2 development for Angina pectoris, Essential hypertension.

Selecal works by blocking beta-1 adrenergic receptors in the heart, reducing heart rate and blood pressure.

Selecal (Tilisolol) is a small molecule drug in the tilisolol class, used to treat Angina pectoris and Essential hypertension. Its commercial status is unknown, but it is used to manage cardiovascular conditions. As a tilisolol, Selecal works by blocking beta-1 adrenergic receptors, which helps to reduce heart rate and blood pressure. This results in improved blood flow to the heart, reducing symptoms of angina and hypertension. However, more information is needed to fully understand its pharmacological profile.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TILISOLOL
Drug class	tilisolol
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your heart is like a racing car engine. Beta-1 adrenergic receptors are like the accelerator pedal, making the engine go faster. By blocking these receptors, Selecal helps slow down the heart rate and reduce blood pressure, making it easier for the heart to pump blood and reducing symptoms of angina and hypertension.

Approved indications

Angina pectoris
Essential hypertension

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Selecal CI brief — competitive landscape report
Selecal updates RSS · CI watch RSS

Frequently asked questions about Selecal

What is Selecal?

Selecal (TILISOLOL) is a tilisolol drug, indicated for Angina pectoris, Essential hypertension.

How does Selecal work?

Selecal works by blocking beta-1 adrenergic receptors in the heart, reducing heart rate and blood pressure.

What is Selecal used for?

Selecal is indicated for Angina pectoris, Essential hypertension.

What is the generic name of Selecal?

TILISOLOL is the generic (nonproprietary) name of Selecal.

What drug class is Selecal in?

Selecal belongs to the tilisolol class. See all tilisolol drugs at /class/tilisolol.

What development phase is Selecal in?

Selecal is in Phase 2.

Drug class: All tilisolol drugs
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Angina pectoris
Indication: Drugs for Essential hypertension

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing